Annual Report

Overview

The report describes CanSinoBIO's 2025 turnaround from loss to profit, with revenue of RMB1,059.4 million and net profit of RMB27.9 million. It highlights the launch and regulatory approval of iPneucia®, a 13-valent pneumococcal conjugate vaccine, alongside continued overseas commercialization. The company also reports recognition as a China Best ESG Employer and inclusion in the S&P Global Sustainability Yearbook (China Edition) 2025.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: 1 January 2025 – 31 December 2025
Publication date: 30 March 2026
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services